AquaBounty Technologies, Inc. (NASDAQ:AQB – Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 423,300 shares, an increase of 452.6% from the December 31st total of 76,600 shares. Currently, 11.7% of the shares of the stock are sold short. Based on an average daily volume of 425,500 shares, the days-to-cover ratio is currently 1.0 days.
Institutional Trading of AquaBounty Technologies
A hedge fund recently raised its stake in AquaBounty Technologies stock. Epiq Partners LLC lifted its stake in AquaBounty Technologies, Inc. (NASDAQ:AQB – Free Report) by 423.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,000 shares of the company’s stock after purchasing an additional 72,000 shares during the quarter. Epiq Partners LLC owned 2.30% of AquaBounty Technologies worth $56,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 8.92% of the stock is currently owned by institutional investors and hedge funds.
AquaBounty Technologies Trading Down 14.7 %
Shares of NASDAQ:AQB traded down $0.12 on Tuesday, reaching $0.70. 227,344 shares of the company traded hands, compared to its average volume of 348,821. The company has a current ratio of 3.02, a quick ratio of 2.98 and a debt-to-equity ratio of 0.05. AquaBounty Technologies has a 52 week low of $0.47 and a 52 week high of $2.79. The business’s 50-day simple moving average is $0.80 and its 200 day simple moving average is $1.08. The stock has a market capitalization of $2.70 million, a P/E ratio of -0.04 and a beta of 1.17.
About AquaBounty Technologies
AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.
Featured Articles
- Five stocks we like better than AquaBounty Technologies
- Canada Bond Market Holiday: How to Invest and Trade
- What Does the Future Hold for Eli Lilly?
- Comparing and Trading High PE Ratio Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
- How to Calculate Inflation Rate
- 3 Consumer Stocks Call Option Traders Are Betting Big On
Receive News & Ratings for AquaBounty Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AquaBounty Technologies and related companies with MarketBeat.com's FREE daily email newsletter.